Answering the Call in Nonadvanced Systemic Mastocytosis
Targeted Approaches to Patient Management
What does an allergist need to know about gastrointestinal presentations in nonadvanced SM and when to perform an endoscopy?
What does an allergist need to know about when to involve dermatology colleagues and the significance of the multidisciplinary team?
Challenges in applying diagnostic criteria for systemic mastocytosis.
Boggs NA, Sun X, Lyons JJ, et al. Blood Adv. 2023;7(13):3150-3154.
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
Giannetti MP, Akin C, Hufdhi R, et al. J Allergy Clin Immunol. 2021;147(4):1497-1501.e1.
Avapritinib versus placebo in indolent systemic mastocytosis.
Gotlib J, Castells M, Elberink HO, et al. NEJM Evid. 2023;2(6):EVIDoa2200339.
Patient perceptions in mast cell disorders.
Jennings SV, Slee VM, Zack RM, et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A. Am J Hematol. 2023;98(7):1097-1116.
Mast cells, mastocytosis, and related disorders.
Theoharides TC, Valent P, Akin C. N Engl J Med. 2015;373(2):163-172.
Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice.
Valent P, Hartmann K, Schwaab J, et al. J Allergy Clin Immunol. 2022;10(8):1999-2012.e1996.
Systemic mastocytosis: multidisciplinary approach.
Zanotti R, Tanasi I, Crosera L, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068.
Clinical Guidelines
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, Orazi A, Hasserjian RP, et al. Blood. 2022;140(11):1200-1228.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.
Khoury JD, Solary E, Abla O, et al. Leukemia. 2022;36(7):1703-1719.
NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Patient Resources
The Mast Cell Disease Society, Inc. (TMS)
TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.
The European Competence Network on Mastocytosis (ECNM)
The goal of the ECNM is to improve disease-recognition, diagnosis, and therapy in patients with mastocytosis in Europe.
National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
CME Opportunity
Making the Call in Nonadvanced Systemic Mastocytosis: Optimizing Multidisciplinary Management
In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the importance of high-sensitivity assays to detect the KIT D816V mutation that is responsible for most cases of nonadvanced SM, the recently updated World Health Organization diagnostic criteria, the various triggers of mast cell activation, symptom assessment techniques, and patient education. The faculty will also discuss individualization of symptom-directed treatment strategies, evolving treatment options, and newly approved targeted therapies for the treatment of nonadvanced SM.
Answering the Call in Nonadvanced Systemic Mastocytosis
Targeted Approaches to Patient Management
| Faculty: | Matthew P. Giannetti, MD ; Anne L. Maitland, MD, PhD; Matthew J. Hamilton, MD ; Lauren M. Madigan, MD |
| Release: | 11/13/2023 |
| Expiration: | 12/11/2023 |
Answering the Call in Nonadvanced Systemic Mastocytosis
Targeted Approaches to Patient Management
| Faculty: | Matthew P. Giannetti, MD ; Anne L. Maitland, MD, PhD; Matthew J. Hamilton, MD ; Lauren M. Madigan, MD |
| Release: | 12/13/2023 |
| Expiration: | 12/13/2024 |
